← All trials
NCT06649721
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 15, 2024
- Primary completion
- Jun 30, 2027
- Completion date
- Jun 30, 2027
- First posted
- Oct 21, 2024
- Last posted
- Nov 11, 2024
- Enrollment
- 120
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Fudan UniversityLead sponsor
- Fudan UniversitySponsor investigator
- Capital Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.